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There is an abundance of information about drugs available on the Web. Data sources range from medicinal
chemistry results, over the impact of drugs on gene expression, to the outcomes of drugs in clinical trials. These
data are typically not connected together, which reduces the ease with which insights can be gained. Linking
Open Drug Data (LODD) is a task force within the World Wide Web Consortium’s (W3C) Health Care and Life
Sciences Interest Group (HCLS IG). LODD has surveyed publicly available data about drugs, created Linked Data
representations of the data sets, and identified interesting scientific and business questions that can be answered
once the data sets are connected. The task force provides recommendations for the best practices of exposing
data in a Linked Data representation. In this paper, we present past and ongoing work of LODD and discuss the
growing importance of Linked Data as a foundation for pharmaceutical R&D data sharing.
Findings
Pharmaceutical research has a wealth of available data
sources to help elucidate the complex biological mechan-
isms that lead to the development of diseases. However,
the heterogeneous nature of these data and their wide-
spread distribution over journal articles, patents and
numerous databases makes searching and pattern discov-
ery a tedious and manual task. From the perspective of a
pharmaceutical research scientist, the ideal data infra-
structure should make it easy to link and search across
open data sources in order to identify novel and mean-
ingful correlations and mechanisms. In this paper, we
present work from the Linked Open Drug Data (LODD)
task force of the World Wide Web Consortium (W3C)
Health Care and Life Science Interest Group (HCLS IG)
that aims to address these issues by harnessing the power
of new web technologies.
The LODD task force works with a set of technologies
and conventions that are now commonly referred to as
Linked Data. The primary goal of the Linked Data
movement is to make the World Wide Web not only
useful for sharing and interlinking documents, but also
for sharing and interlinking data at very detailed levels.
The movement is driven by the hypothesis that these
technologies could revolutionize global data sharing,
integration and analysis, just like the classic Web revolu-
tionized information sharing and communication over
the last two decades.
Linked Data is based on a set of principles and stan-
dard recommendations created by the W3C. Single data
points are identified with Hypertext Transfer Protocol
(HTTP, [1]) Uniform Resource Identifiers (URIs). Similar
to how a Web page can be retrieved by resolving its
HTTP URI (e.g., ‘http://en.wikipedia.org/wiki/Preseni-
lin’), data about a single entity in the Linked Data space
can be retrieved by resolving its HTTP URI (e.g. ‘http://
dbpedia.org/resource/Presenilin’). However, instead of
Web pages, the primary data model of Linked Data is the
Resource Description Framework (RDF, [2]). In RDF,
entities, their relations and properties are described with
simple subject-predicate-object triples. Out of these sim-
ple triples, sophisticated networks of interlinked data can
be built, potentially spanning over several different loca-
tions on the web. Since every entity in this network can
be resolved through HTTP, it is possible to navigate and
aggregate the globally distributed data, enabling the
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made the Web successful.
There is a large array of other standard recommenda-
tions based on RDF. Networks of RDF data can be quer-
ied by an intuitive and powerful query language called
SPARQL [3]. The Web Ontology Language (OWL,[ 4 ] )
makes it possible to do complex logical reasoning and
consistency checking of RDF/OWL resources. These rea-
soning capabilities can be used to harmonize heteroge-
neous data structures. Another related standard is RDFa
[5], which makes it possible to embed RDF statements
into human-readable Web pages, effectively bridging the
domains of human-readable and machine-readable data.
Chen at al. provide an extensive review of RDF/OWL -
based projects relevant to drug discovery in a recent
publication [6].
To date, participants of the LODD project have made
twelve open-access datasets relevant to pharmaceutical
research and development available as Linked Data
(table 1). These are DrugBank [7], ClinicalTrials.gov
[8,9], DailyMed [10], ChEMBL [11,12], Diseasome [13],
TCMGeneDIT [14,15], SIDER [16], STITCH [17], the
Medicare formulary and the three most recent additions,
RxNorm [18], Unified Medical Language System
(UMLS, [19]) and the WHO Global Health Observatory
[20]. To be kept up to date, the original datasets are
periodically retrieved and the Linked Data representa-
tions are refreshed. The URIs for representing entities in
the linked datasets are stable and are chosen by the
LODD participants.
Not all of these datasets can currently be considered
fully ‘open’ as outlined by the Panton Principles [21]. For
example, some of the source have non-commercial
clauses in the license agreement. The LODD project is
actively exploring the exact conditions for modification
and redistribution defined by the data providers, and
acknowledges the limitations with respect to openness
some of these datasets currently have.
The LODD datasets are linked with each other, as well
as with datasets provided by other Linked Data projects,
such as Bio2RDF [22] and Chem2Bio2RDF [23], as well
as primary data providers that offer their resources in
RDF, such as UniProt [24,25] and the Allen Brain Atlas
[26]. The links between datasets are depicted in Figure 1.
Overall, there are several dozens of biomedically relevant
linked datasets available to date.
While the number of linked biomedical datasets has
grown significantly over the last years, there is still a
marked lack of mature applications that enable end-users
to explore and query these datasets. Linked data browsers
such as Marbles [28] or Sig.ma [29,30] are currently too
generic for most end-users (although they can be very
helpful for developers). These shortcomings are
a d d r e s s e db yT r i p l e M a p( F i g u r e2 ,[ 3 1 ] ) ,an e ww e b -
based application that can be used for the navigation,
visualization and analysis of the LODD resources and
other RDF datasets. To illustrate the use of TripleMap
and the LODD resources, the following simple scenario
could be imagined: A researcher interested in Alzhei-
mer’s Disease decides to find out everything that they
can about the disease by querying an integrated version
of the Linking Open Drug Data (LODD) sets. They open
TripleMap and start their search by typing “Alzheimer’s”
into the Diseases search box. As they type, TripleMap
provides a dynamic auto-complete list of all of the dis-
ease related entities across all LODD data sets that match
the search string. The researcher selects “Alzheimer’s
Disease” and drags and drops it into the TripleMap
workspace. Now, the researcher can view a range of
information known about the properties of the disease in
the right-hand “properties panel” including links out to
Pubmed, Online Mendelian Inheritance in Man (OMIM,
[32]), Uniprot [24] and other sources. These sources pro-
vide the user with rapid access to overview information
about the disease.
The researcher is now interested in discovering entities
that are associated with Alzheimer’s Disease. They select
the Alzheimer’s Disease icon in the workspace and the
system automatically shows them a number of associated
disease genes provided by Diseasome, compounds pro-
vided by DrugBank and DailyMed, and clinical trials pro-
vided by LinkedCT. The researcher starts to explore
relationships between entities by selecting two genes,
presenilin (PSEN1) and amyloid precursor protein (APP),
and dragging them into the workspace. In addition to
finding genes related to Alzheimer’s Disease, the user is
interested in compounds known to be related to the dis-
ease. The user finds several compounds and pulls them
into the workspace. The user is also interested in finding
out what clinical trials are currently being run for Alzhei-
mer’s Disease and the system shows 200 such trials. With
a simple click and drag action they pull all 200 trials into
the workspace. As entities are added to the workspace, if
there are known associations between them, those asso-
ciations are also shown to the user as semantically tagged
edges. This ability to show a researcher unexpected asso-
ciations between entities that are related to their field of
interest is at the heart of the value of an application like
TripleMap and the extensive, rich, interconnected data
available in the LODD data sets.
Linked Data as an emerging technology is still not free
from shortcomings. A major problem is the heterogene-
ity in how data is modeled. Even when the entities
between datasets are mapped to each other, it can still
be difficult to intuitively write queries that span datasets
because of this heterogeneity. This problem is being
addressed by another task force of the W3C HCLSIG,
which aims to bridge the data in the growing number of
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ogy, the translational medicine ontology (TMO, [33]).
Another problem is how to efficiently query RDF in dis-
tributed SPARQL databases without requiring the aggre-
gation of RDF data at a central location. Again, this is
addressed by ongoing work on query federation by
members of the W3C HCLS IG [34]. Finally, there has
been a lack of applications with good user interfaces to
make Linked Data resources accessible to end-users
outside the biomedical informatics community. This is
addressed by several ongoing endeavors such as the Eur-
opean Khresmoi project [35].
A challenge to creating linked data that is specific to the
domain of chemistry is the provision of chemical identi-
fiers. It is for this reason that W3C HCLS IG supports
efforts to standardize unique identifiers for chemical com-
pounds such as the IUPAC International Chemical Identi-
fier (InChI, [36]).
Table 1 The current LODD datasets.Further information about content and accessibility (URIs, SPARQL endpoints) of
these linked datasets can be found online at [27]
Name Short Description Size and coverage
(rounded)
Sources Provider (1. original
dataset, 2. RDF version
of dataset)
DrugBank Chemical, pharmacological and pharmaceutical








1. University of Alberta




Information about clinical trials 9.8 million triples,
80,000 trials
Data submitted by study
sponsors or their
representatives




DailyMed Information about approved prescription drugs,
including FDA approved labels (package inserts)
164,000 triples; 4,000
drugs
Package inserts, data from
the US food and drug
administration (FDA)
1. US National Library of
Medicine
2. Free University of
Berlin
ChEMBL Information on drugs, e.g., activity against drug
targets such as proteins, chemical properties.
Linked to primary literature









Diseasome Characteristics of disorders and disease genes
linked by known disease-gene associations
91,000 triples; 2,600
genes
Generated from data in
Online Mendelian Inheritance
in Man (OMIM)
1. Consortium of several
labs




Gene-disease-drug associations mined from
literature about Chinese medicine
117,000 triples Mined from research articles 1. National Taiwan
University
2. Oxford University





FDA databases 1. US National Library of
Medicine
2. Stony Brook School of
Medicine
UMLS Unified Medical Language System (UMLS) sources
available without restrictions
55 million triples Ontologies created by third
parties
1. US National Library of
Medicine
2. Stony Brook School of
Medicine
SIDER Reported adverse effects of marketed drugs 193,000 triples; 63,000
adverse effect reports
Mined package inserts 1. European Molecular
Biology Laboratory,
Heidelberg
2. Free University of
Berlin











2. Free University of
Berlin
Medicare The Medicare formulary 44,500 triples; 6800
drugs
Primary data 1. US Government





Data and statistics for infectious diseases at
country, regional, and global levels.






Statistics about size and coverage were last checked on March 24, 2011.
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Linked Data with examples of projects being presented
by Eli Lilly, Johnson & Johnson and UCB Pharma.
While the adoption of Linked Data is still not yet very
widespread in individual companies, it is on the agenda
of several large-scale cross-pharma projects. An Eur-
opean project, the Open Pharmacological Space (OPS)
Open PHACTS (Pharmacological Concept Triple Store)
project under the European Innovative Medicines Initia-
tive (IMI, [37]) wants to create an open source, open
standards and open access infrastructure to enable inte-
gration of chemical and biological data to support drug
discovery. The project intends to reach this goal by
using Linked Data and managing the data in an RDF tri-
ple store. Collaboration across several IMI projects
should also encourage the coordinated use of Linked
Data to enhance data sharing. On the pre-competitive
data sharing side of pharmaceutical informatics, the
members of the Pistoia Alliance [38] are developing the
Semantically Enriched Scientific Literature (SESL) pro-
ject. The goal of SESL is to test the feasibility of execut-
ing federated querying across full text literature and
bioinformatics databases by performing SPARQL queries
on a triple store of assertions from the chosen data
sources. The PRISM Forum [39] has also issued a letter
recommending the adoption of Linked Data that has
been supported by its membership of 15 of the top 20
pharmaceutical companies. The European OpenTox
project [40,41] uses RDF as a standard for the exchange
of predictive toxicology related data. The OpenTox fra-




































Figure 1 A graph of some of the LODD datasets (dark grey),
related biomedical datasets (light grey), related general-
purpose datasets (white) and their interconnections. Line
weights correspond to the number of links. The direction of an
arrow indicates the dataset that contains the links, e.g., an arrow
from A to B means that dataset A contains RDF triples that use
identifiers from B. Bidirectional arrows usually indicate that the links
are mirrored in both datasets.
Figure 2 TripleMap www.triplemap.com is a web-based application that provides a rich, dynamic, visual interface to integrated RDF
datasets such as the LODD. On the left hand side of the application a researcher uses an icon-based menu representing biomedical
entities such as compounds, diseases and assays to search for entities and view their associations. Entities can be dragged and dropped
from the icon menu into the application’s zoomable workspace. In the middle of the application the user navigates maps of entities and their
associations in the zoomable workspace much like users of Google Maps are able to scan and zoom into and out of geographically based maps.
On the right hand side of the application the user can view an integrated set of all of the available properties for a selected entity. As entities
are added to the workspace the system automatically generates semantically tagged edges between associated entities.
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computing facility.
Proprietary systems for providing integrated pharma-
ceutical data exist. The Accelrys/Symyx products [42]
are popular examples, and can be both accessed online
or installed locally. Accessing the data provided by these
products often requires proprietary tools and internal
installations also require ongoing work to be kept up-
to-date. Furthermore, many of these products are based
on individual databases that are not linked. Since the
amount of data and the number of potential data
sources is growing, it will become harder for single soft-
ware vendors to create all-encompassing solutions. The
nascent Linked Data infrastructure could help to make
the creation of integrated solution more sustainable,
easier to maintain and vendor-neutral.
Over the next years, the LODD group will continue to
work jointly with both academic and industry partners. It
w i l la i mt ob e c o m ea nu m b r e l l af o ro t h e rL i n k e dD a t a
providers and consumers in the pharmaceutical domain,
assisting with documentation, interlinking, quality man-
agement, and compliance with standard formats and
vocabularies. Another strand of work will focus on how
to integrate public Linked Data with non-public, in-
house datasets of biomedical research institutions and
pharmaceutical companies.
The LODD task force is open to new participants and
interested individuals or groups are invited to get in
contact with the authors of this paper.
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